SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

ATM Sales Summary (3-2009 thru 6-30-2012)…

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
cjgaddy Member Profile
 
Followed By 67
Posts 5,220
Boards Moderated 1
Alias Born 01/24/04
160x600 placeholder
Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices "GlobeNewswire Inc." - 10/19/2017 8:05:00 AM
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals "PR Newswire (US)" - 10/10/2017 12:59:00 PM
CORRECTING and REPLACING Announcing VanEck Vectors Equity ETF’s September 2017 Distributions "Business Wire" - 10/2/2017 12:35:00 PM
Announcing VanEck Vectors Equity ETF’s September 2017 Distributions "Business Wire" - 9/29/2017 5:25:00 PM
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Lit... "GlobeNewswire Inc." - 9/25/2017 8:05:00 AM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 9/19/2017 2:51:59 PM
Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition "GlobeNewswire Inc." - 9/19/2017 8:05:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/14/2017 5:21:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/14/2017 5:19:50 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 9/11/2017 5:14:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 5:04:28 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/11/2017 5:02:13 PM
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments "GlobeNewswire Inc." - 9/11/2017 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 3:37:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/11/2017 3:35:34 PM
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices "GlobeNewswire Inc." - 9/11/2017 8:05:00 AM
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combinati... "GlobeNewswire Inc." - 9/7/2017 8:10:00 AM
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017 "GlobeNewswire Inc." - 9/6/2017 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/5/2017 4:31:30 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 9/5/2017 4:05:00 PM
Proxy Statement - Contested Solicitations (preliminary) (prec14a) "Edgar (US Regulatory)" - 8/29/2017 5:23:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 5:18:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 5:17:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 5:17:43 PM
cjgaddy   Saturday, 07/21/12 11:34:42 AM
Re: cjgaddy post# 84279
Post # of 314879 
ATM Sales Summary (3-2009 thru 6-30-2012)…

ATM = “At-The-Market Sales Issuance”

I. WM-SMITH:
• $7.5mm ATM/Wm.SMITH 3-26-09: $7,500,000gr. / 2,150,759sh. = $3.49/sh. (commiss: 3%)
• $25mm ATM/Wm.SMITH 7-14-09: $25,000,000gr. / 7,569,314sh. = $3.30/sh. (commiss: 3%/1st$15mm, then 2%)
*Total Raised via WmSmith ATM Sales thru 7-31-10:
. . . . $32,500,000gr. / 9,720,073sh. = $3.34/sh.

II. MLV 6-2010: http://www.mlvco.com
$15mm ATM/MLV 6-22-10 (commiss: 2%) Form424: http://tinyurl.com/24txkxb
• Sold 6/22/10–10/31/10: $6,840,000gr. / 4,031,018sh. = $1.70/sh.
• Sold 11/1/10–11/30/10: $7,407,000gr. / 4,711,611sh. = $1.57/sh.
• Sold 12/1/10–1/31/11: $753,000gr. / 471,744sh. = $1.60/sh.
*Total Raised via MLV June’10 ATM Sales thru 1-31-11:
. . . . $15,000,000gr. / 9,214,373 = $1.63/sh.

III. MLV 12-2010: “Dec’10 AMI Agreement” http://www.mlvco.com
$75mm ATM/MLV 12-29-10 (commiss: max=5%) Form8K: http://tinyurl.com/2a6w76g
(pursuant to $75mm S-3 Shelf Reg. filed 12-17-10: http://tinyurl.com/2469b2d )
• Sold 12/29/10-1/31/11: $6,460,000gr. / 2,385,862sh. = $2.71/sh.
• Sold 2/1/11-2/28/11: $2,358,000gr. / 998,142sh. = $2.36/sh.
• Sold 3/1/11-4/30/11: $4,470,000gr. / 1,840,487sh. = $2.43/sh.
• Sold 5/1/11-7/31/11: $3,713,000gr. / 1,912,576sh. = $1.94/sh.
• Sold 8/1/11-10/31/11: $5,582,000gr. / 4,727,840sh. = $1.18/sh.
• Sold 11/1/11-1/31/12: $10,961,000gr. / 10,308,025sh. = $1.06/sh.
• Sold 2/1/12-2/29/12: $5,871,000gr. / 5,726,946sh. = $1.03/sh.
• Sold 3/1/12-4/30/12: $1,263,000gr. / 2,198,543sh. = $.57/sh.
• Sold 5/1/12-6/30/12: $1,496,000gr. / 2,752,691sh. = $.54/sh.
*Total Raised via MLV Dec’10 ATM Sales thru 6-30-2012:
. . . . $42,174,000gr. / 32,851,112 = $1.28sh.

TOTAL ALL A-T-M SALES – INCEPTION (3-2009) THRU 6-30-2012:
==> $89,674,000gr. / 51,785,558sh. = $1.73/sh.

- - - - - - - - - -
10-31-11 10Q: “During the 6mos. 10-31-11, we sold 6,440,416 shares of our common stock at mkt-prices for gross proceeds of $9,295,000 under the Dec’10 AMI Agreement before deducting commissions and other issuance costs of $260,000”
1-31-12 10Q: “During the 9mos. ended 1-31-12, we sold 16,948,441 shares of our common stock at mkt-prices for gross proceeds of $20,256,000 under the Dec’10 AMI Agreement before deducting commissions and other issuance costs of $482,000. …During Feb.2012, we sold an addl. 5,726,946 shares of common stock at market prices under the Dec’10 AMI Agreement in exchange for aggregate gross proceeds of $5,871,000. As of 2-29-12, gross proceeds of $38,644,000 remained available under our 2 effective shelf registration statements.”
4-30-12 10K: “Under the Dec. 2010 AMI Agreement with MLV …for aggregate gross proceeds of up to $75,000,000… During FY’s 2011 (5’10-4’11) and 2012 (5’11-4’12), we sold 30,098,421 shares of common stock at market prices under the Dec.2010 AMI for aggregate gross proceeds of $40,678,000 before deducting commissions & other issuance costs of $917,000. As of April 30, 2012, aggregate gross proceeds of up to $27,382,000 remained available under the Dec.2010 AMI… Subsequent to April 30, 2012 and through June 30, 2012, we sold 2,752,691 shares of common stock at mkt prices under the Dec.2010 AMI for aggregate gross proceeds of $1,496,000.

ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8

Shelf-Date Registration# Amt-Registered
• Jan2007 #333-139975 $30,000,000
• July2009 #333-160572 $50,000,000
• Dec2010 #333-171252 $75,000,000
• Mar9-2012 “PPHM files shelf to sell up to $150mm common stock, warrants”, S3: http://tinyurl.com/7dl7pjm - CFO Paul Lytle, 3-9-12/CC: ”In closing, let me say that we are planning for success as we get closer to unblinding data from our 2nd-line NSCLC study and reporting several other clinical data points from our other ongoing trials. And it's important to note that while we always seek other non-dilutive opportunities to fund our future development efforts, it is always prudent to prepare for other ways to fund our operations. In line with this strategy, we will be filing a new shelf-registration statement later today as a potential measure to assist us at advancing our pipeline of novel drug candidates. We look forward to keeping you updated on our progress. . .” PL/Q&A: “And our goal is really to plan for success here and having an effective shelf in place allows us to plan for success. Obviously, our goal is to look at potential partnerships as we move forward to help fund these bigger Phase III studies that we're anticipating based on promising data. But we want to be prepared internally to have an additional vehicle in place; assuming you can't determine when and the time frame of a potential partnership. So we just want to make sure we're taking prudent measures internally to prepare ourselves for success, and in a shelf that will last 3 years, once it’s declared effective. ”
• CFO Paul Lytle, 7-16-12/CC: ”In addition to our focus on growing Avid revenues, our next immediate focus is to secure a less-dilutive debt-financing vehicle, similar to a term loan. Recognizing the growing value in the Avid asset, and the strong clinical data in 2nd-Line NSCLC, we are pursuing a non-convertible-type loan in the range of $20-30mm. We will keep you updated as we get closer to a possible transaction.” ( http://tinyurl.com/cs7spbz )


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist